Fidelity National Financial Inc. Invests $20.23 Million in Abbott Laboratories $ABT

Fidelity National Financial Inc. purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) during the second quarter, HoldingsChannel reports. The institutional investor purchased 223,000 shares of the healthcare product maker’s stock, valued at approximately $20,235,000. Abbott Laboratories makes up about 0.6% of Fidelity National Financial Inc.’s investment portfolio, making the stock its 13th largest position.

A number of other hedge funds also recently added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter worth $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the 4th quarter worth about $26,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott’s First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott’s next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Analyst Upgrades and Downgrades

ABT has been the topic of several research analyst reports. Citigroup upped their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. TD Cowen lifted their target price on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday. Bank of America lowered their price target on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, UBS Group dropped their price target on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Stock Performance

ABT opened at $112.63 on Friday. The company’s 50 day moving average is $102.61 and its 200 day moving average is $100.22. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a market cap of $194.89 billion, a price-to-earnings ratio of 36.45, a PEG ratio of 2.16 and a beta of 0.59. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm’s revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.